Brief: Compass Therapeutics Receives FDA Fast Track Designation For The Investigation Of CTX-009 In Combination With Paclitaxel
25/04/2024 13:56
April 25 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR THE
INVESTIGATION OF CTX-009 IN COMBINATION WITH PACLITAXEL FOR THE
TREATMENT OF PATIENTS WITH METASTATIC OR LOCALLY ADVANCED
BILIARY TRACT TUMORS THAT HAVE BEEN PREVIOUSLY TREATED
* COMPASS THERAPEUTICS INC. - TOP-LINE DATA READOUT FOR
COMPANION-002, COMPANY'S RANDOMIZED PHASE 2/3 BTC U.S. STUDY, IS
EXPECTED BY END OF 2024
Source text for Eikon: ID:nGNXbGR66v
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback